Overvægt kliniske forsøg i Indiana
16 studier for Overvægt søger deltagere på steder i Indiana.
Byer i Indiana
Officiel studietekst (engelsk)
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- IU Health - Riley Physicians Endo-Diab, Indianapolis
RekruttererFase 3
Alder 8 til 18 · Alle køn · Opdateret 30. sep. 2026 · NCT07253285AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Midwest Inst For Clin Res, Indianapolis
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07720271A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- Midwest Inst For Clin Res, Indianapolis
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07668414A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- MediSphere Medical Research Center, LLC, Evansville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07595549Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
RekruttererFase 3
Alder 18 til 70 · Alle køn · Opdateret 24. sep. 2026 · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Riley Hospital for Children, Indianapolis
RekruttererFase 3
Alder 6 til 17 · Alle køn · Opdateret 24. sep. 2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
RekruttererFase 3
Alder 18 til 70 · Alle køn · Opdateret 24. sep. 2026 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- DM Clinical Research - Indianapolis, Indianapolis
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07282600Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Cardiovascular Research of Northwest Indiana LLC, Munster
- Velocity Clinical Research - Valparaiso, Valparaiso
RekruttererFase 3
Alder 45 til 99 · Alle køn · Opdateret 22. sep. 2026 · NCT07037433Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Qualmedica Research, LLC, Evansville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07353931A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Evansville
- AURORA-1 Clinical Site, Indianapolis
- AURORA-1 Clinical Site, Valparaiso
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Evansville
- AURORA-2 Clinical Site, Indianapolis
- AURORA-2 Clinical Site, Valparaiso
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT07743450A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Investigators Research Group, Brownsburg
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 14. sep. 2026 · NCT06897475A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
- The Indiana Clinical Trials Center, PC, Plainfield
RekruttererFase 4
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT06857942A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- Midwest Inst For Clin Res, Indianapolis
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT07745504Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- Indiana University, Indianapolis
Rekrutterer
Alder 18 til 45 · Kvinder · Opdateret 24. jun. 2026 · NCT05124808Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.